Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1975 1
1976 1
1979 1
1986 2
1987 3
1988 1
1989 3
1990 5
1991 2
1992 2
1993 1
1994 4
1995 4
1996 7
1997 7
1998 4
1999 5
2000 2
2001 8
2002 15
2003 17
2004 25
2005 34
2006 31
2007 44
2008 59
2009 68
2010 77
2011 83
2012 112
2013 105
2014 83
2015 103
2016 91
2017 112
2018 116
2019 109
2020 97
2021 128
2022 116
2023 116
2024 117
2025 139
2026 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,851 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. Among authors: choi ch. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. J Clin Oncol. 2025. PMID: 39591551 Free PMC article. Clinical Trial.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Among authors: choi ch. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. Grisham R, et al. Among authors: choi ch. Int J Gynecol Cancer. 2025 Nov;35(11):101832. doi: 10.1136/ijgc-2024-005919. Epub 2025 Apr 19. Int J Gynecol Cancer. 2025. PMID: 39375168 Free article.
Authors' Reply.
Lim S, Chung YE, Seo JH, Choi CH, Lee Y, Kato K, Lee YL, Chen YL. Lim S, et al. Among authors: choi ch. J Minim Invasive Gynecol. 2025 Aug 11:S1553-4650(25)00295-X. doi: 10.1016/j.jmig.2025.08.007. Online ahead of print. J Minim Invasive Gynecol. 2025. PMID: 40803505 No abstract available.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Marth C, et al. Among authors: choi ch. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. Int J Gynecol Cancer. 2022. PMID: 34799418 Free PMC article.
Unbiased matchmaking.
Chan CKW, Lau SHG, Choi CHJ. Chan CKW, et al. Among authors: choi chj. Nat Chem Biol. 2022 Sep;18(9):921-923. doi: 10.1038/s41589-022-01108-1. Nat Chem Biol. 2022. PMID: 35953548 No abstract available.
Cell-nano interactions of polydopamine nanoparticles.
Liang Z, He Y, Ieong CS, Choi CHJ. Liang Z, et al. Among authors: choi chj. Curr Opin Biotechnol. 2023 Dec;84:103013. doi: 10.1016/j.copbio.2023.103013. Epub 2023 Oct 26. Curr Opin Biotechnol. 2023. PMID: 37897860 Review.
Heteroatom-Substituted Reflashed Graphene.
Scotland P, Eddy L, Chen J, Chen W, Beckham JL, Wyss KM, Choi CH, Advincula PA, Lathem A, Onah OE, Han Y, Tour JM. Scotland P, et al. Among authors: choi ch. ACS Nano. 2025 Apr 1;19(12):11987-11998. doi: 10.1021/acsnano.4c16959. Epub 2025 Mar 21. ACS Nano. 2025. PMID: 40117566
1,851 results